MA-LINEDATA
Linedata, a global provider of credit and asset management technology, data and services, today announced it is the first technology vendor to seamlessly integrate Environmental, Social, and Governance (ESG) data into asset managers’ workflows through collaboration with leading independent provider Arabesque S-Ray . A wide range of ESG data assets feeds directly into Linedata’s software to help managers meet growing demands from regulators and investors for greater transparency over ESG funds, and to provide a competitive edge through sustainable positioning and differentiated product offerings.
Arabesque S-Ray’s quantitative data tool uses machine learning to crunch the sustainability performance of over 8,000 of the world’s largest listed companies, and directly integrates with Linedata’s portfolio and order management solutions for unparalleled ease of use. It is available to Linedata clients in Europe, Asia, and North America.
“We believe economic value creation can go hand in hand with environmental stewardship, social inclusion, and sound governance,” noted Georg Kell, Chairman of the Arabesque Group, and founding Executive Director of the United Nations Global Compact. “Our agreement with Linedata empowers more asset managers to make better decisions for a sustainable future.”
Positioning powerful ESG intelligence at the fingertips of Linedata’s over 450 global asset management clients helps managers support ESG decision-making and adapt to evolving requirements under Europe’s new Sustainable Finance Disclosure Regulation (SFDR) and the United States’ new ESG agenda.
The move also marks an expansion of Linedata’s Data Management Service, a key component of its cloud-based Asset Management Platform - AMP launched last year. It offers an innovative commercial model which gives basic ESG and UN Global Compact scores to users of Linedata software, and the flexibility to access premium data on a usage basis, a break from the industry standard.
“Linedata is committed to helping market participants to make more and better ESG driven decisions. With sustainable fund assets hitting a record $1.7 trillion in 20201 , asset managers recognize ethical and sustainable funds as a major growth opportunity,” said Gary Brackenridge, Linedata’s Global Head of Asset Management. “The combination of Arabesque’s market-leading ESG data seamlessly integrated into Linedata’s cloud-based portfolio workflows with a unique usage model fits with what we know clients are looking for: commercial flexibility, high-value content and excellent user experience.”
Providing instant access to Arabesque S-Ray’s data supports the wider industry shift to ESG investing, while removing a major operational burden from asset managers. The ability to leverage independently validated ESG scores streamlines and accelerates the development of ethical, sustainable and funds and in turn helps guide which companies consciously minded investors and consumers choose to support.
Users benefit from ESG data insights throughout the entirety of their investment operations:
- Score, rebalance, and create new ESG portfolio strategies, products, and workflows
- Integrate ESG factors into pre- and post-trade Compliance at asset and fund level
- Manage regulatory and investor transparency and reporting with dashboards, screening, and monitoring tools
To learn more about Linedata’s Data Management Service - ESG Inside, visit linedata.com/ESG
Linedata is pleased to have won Best Data Management Solution at Hedgeweek European Awards 2021 at a virtual gala on Thursday March 11, 2021.
1 Sustainable investment indexes outperform and protect on the downside: Morningstar , 16.02.21
ABOUT ARABESQUE S-RAY
S-Ray® is an AI-based tool developed by Arabesque that analyses the sustainability performance of approximately 8,000 of the world’s largest listed corporations using self-learning quantitative models and data scores. The technology systematically combines over 200 ESG metrics with news signals from over 30,000 sources across 170 countries. It is the first tool of its kind to rate companies on the normative principles of the United Nations Global Compact (GC Score). Additionally, S-Ray provides an industry-specific assessment of companies’ performance on financially material sustainability criteria (ESG Score). Both scores are combined with a preferences filter that assesses a company’s business involvements. S-Ray daily data products and services are used by some of the world’s leading financial institutions, investors, corporations, and consultants.
ABOUT LINEDATA
With 20 years’ experience and 700 clients in 50 countries, Linedata’s 1100 employees in 20 offices provide global humanized technology solutions and services for the asset management and credit industries that help its clients to evolve and to operate at the highest levels.
Headquartered in France, Linedata achieved revenues of EUR 161.0 million in 2020 and is listed on Euronext Paris compartment B FR0004156297-LIN – Reuters LDSV.PA – Bloomberg LIN:FP.
linedata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom